Quantum-Si (NASDAQ:QSI – Get Free Report) and Quanterix (NASDAQ:QTRX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.
Earnings and Valuation
This table compares Quantum-Si and Quanterix”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quantum-Si | $2.44 million | 119.31 | -$101.34 million | ($0.46) | -2.89 |
| Quanterix | $138.90 million | 0.98 | -$107.15 million | ($2.63) | -1.10 |
Quantum-Si has higher earnings, but lower revenue than Quanterix. Quantum-Si is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings for Quantum-Si and Quanterix, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quantum-Si | 1 | 1 | 2 | 0 | 2.25 |
| Quanterix | 1 | 2 | 0 | 0 | 1.67 |
Quantum-Si currently has a consensus target price of $2.50, indicating a potential upside of 87.97%. Quanterix has a consensus target price of $3.25, indicating a potential upside of 12.46%. Given Quantum-Si’s stronger consensus rating and higher probable upside, analysts plainly believe Quantum-Si is more favorable than Quanterix.
Institutional and Insider Ownership
39.9% of Quantum-Si shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 22.0% of Quantum-Si shares are owned by company insiders. Comparatively, 1.5% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Quantum-Si and Quanterix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quantum-Si | -6,138.26% | -47.12% | -43.18% |
| Quanterix | -80.25% | -26.09% | -19.03% |
Volatility and Risk
Quantum-Si has a beta of 3.26, meaning that its share price is 226% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.
Summary
Quantum-Si beats Quanterix on 8 of the 14 factors compared between the two stocks.
About Quantum-Si
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.
About Quanterix
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Receive News & Ratings for Quantum-Si Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum-Si and related companies with MarketBeat.com's FREE daily email newsletter.
